Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC Pink: VYYRF) announced on September 9, 2026, that it has achieved the first milestone under its non-dilutive Collaboration and Funding Agreement with Bayer AG, triggering a USD $1 million payment. The company submitted a complete feasibility work plan and timetable that was approved by Bayer, marking progress toward establishing a North American source of high-purity iodine for use in contrast media drugs.
The Houston R&D team successfully proved out Voyageur's proprietary Mueller iodine extraction process, producing 99.8% purity iodine from Anadarko Basin produced water. These results provided the technical confirmation needed for Bayer to advance the program. The transportable pilot plant is nearing completion and is scheduled to begin field operations this fall. With this milestone, Voyageur has received USD $1,350,000 of the USD $2,350,000 committed by Bayer, including the initial USD $350,000 paid in March 2026. The remaining USD $1,000,000 (Milestone Payment II) is scheduled for release upon completion of the FEL-3 feasibility study.
“Achievement of this first milestone under our agreement with Bayer is an important step forward for Voyageur,” said Brent Willis, President and CEO. “It confirms that the feasibility work is advancing as planned and triggers the first major non-dilutive payment under the collaboration. This capital is expected to further accelerate our iodine supply strategy and move us closer to validating a reliable North American source of high-purity iodine for use in contrast media drugs.”
The project proposes a staged rollout, beginning with 200 tonnes per year iodine production, with potential expansion to 1,000 tonnes per year. Successful completion of the feasibility study could lead to a second phase and a long-term offtake supply agreement with Bayer. The funding will support continued feasibility work through 2026, including engineering support from Fluor Corporation (NYSE: FLR), which has been assisting with engineering, thermodynamic modeling, and project planning.
The global contrast media market is estimated at approximately USD $7.06 billion, according to market research. Voyageur's vertically integrated strategy aims to improve supply-chain security, reduce reliance on imported raw materials, and lower operating costs for medical imaging contrast agents. This collaboration with Bayer, combined with technical support from Fluor, strengthens the foundation for scalable domestic iodine production.
Willis added: “Voyageur is focused on building multiple potential revenue streams through a staged commercialization strategy. This includes near-term opportunities from barium contrast sales, iodine sales under the Bayer collaboration, and longer-term opportunities from barium and iodine-based contrast drug sales.” The company plans to provide further updates as feasibility work progresses.
